Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 231

1.

Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Srivastava A, Kahan M, Nader M.

Can Fam Physician. 2017 Mar;63(3):200-205. Review.

2.

Evaluation of 6 remote First Nations community-based buprenorphine programs in northwestern Ontario: Retrospective study.

Mamakwa S, Kahan M, Kanate D, Kirlew M, Folk D, Cirone S, Rea S, Parsons P, Edwards C, Gordon J, Main F, Kelly L.

Can Fam Physician. 2017 Feb;63(2):137-145.

3.

Opioid receptor agonists may favorably affect bone mechanical properties in rats with estrogen deficiency-induced osteoporosis.

Janas A, Folwarczna J.

Naunyn Schmiedebergs Arch Pharmacol. 2017 Feb;390(2):175-185. doi: 10.1007/s00210-016-1295-6. Epub 2016 Nov 28.

4.

Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.

Midgard H, Bramness JG, Skurtveit S, Haukeland JW, Dalgard O.

PLoS One. 2016 Nov 15;11(11):e0166451. doi: 10.1371/journal.pone.0166451. eCollection 2016.

5.

Intranasal buprenorphine alone and in combination with naloxone: Abuse liability and reinforcing efficacy in physically dependent opioid abusers.

Walsh SL, Nuzzo PA, Babalonis S, Casselton V, Lofwall MR.

Drug Alcohol Depend. 2016 May 1;162:190-8. doi: 10.1016/j.drugalcdep.2016.03.005. Epub 2016 Mar 14.

6.

Efficacy of Buprenorphine/Naloxone Rapidly Dissolving Sublingual Tablets (BNX-RDT) After Switching From BNX Sublingual Film.

Gunderson EW, Sumner M.

J Addict Med. 2016 Mar-Apr;10(2):124-30. doi: 10.1097/ADM.0000000000000201.

7.

Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.

Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, Timko C, Frayne SM, Smelson D, Oliva E, Binswanger I.

Drug Alcohol Depend. 2016 Mar 1;160:222-6. doi: 10.1016/j.drugalcdep.2016.01.013. Epub 2016 Jan 24.

8.

Management of patients with issues related to opioid safety, efficacy and/or misuse: a case series from an integrated, interdisciplinary clinic.

Becker WC, Merlin JS, Manhapra A, Edens EL.

Addict Sci Clin Pract. 2016 Jan 28;11(1):3. doi: 10.1186/s13722-016-0050-0.

9.

A Systematic Review on the Use of Psychosocial Interventions in Conjunction With Medications for the Treatment of Opioid Addiction.

Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D.

J Addict Med. 2016 Mar-Apr;10(2):93-103. doi: 10.1097/ADM.0000000000000193. Review.

10.

Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys.

Saccone PA, Zelenock KA, Lindsey AM, Sulima A, Rice KC, Prinssen EP, Wichmann J, Woods JH.

J Pharmacol Exp Ther. 2016 Apr;357(1):17-23. doi: 10.1124/jpet.115.231134. Epub 2016 Jan 22.

11.

Presence or Absence of QTc Prolongation in Buprenorphine-Naloxone Among Youth With Opioid Dependence.

Poole SA, Pecoraro A, Subramaniam G, Woody G, Vetter VL.

J Addict Med. 2016 Jan-Feb;10(1):26-33. doi: 10.1097/ADM.0000000000000176.

12.

Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial.

Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, Hatch-Maillette M, Jelstrom E, Wiest K, McLaughlin P, Ling W.

Addiction. 2016 Apr;111(4):695-705. doi: 10.1111/add.13238. Epub 2016 Jan 13.

13.

Short term health-related quality of life improvement during opioid agonist treatment.

Nosyk B, Bray JW, Wittenberg E, Aden B, Eggman AA, Weiss RD, Potter J, Ang A, Hser YI, Ling W, Schackman BR.

Drug Alcohol Depend. 2015 Dec 1;157:121-8. doi: 10.1016/j.drugalcdep.2015.10.009. Epub 2015 Oct 25.

14.

A Multidisciplinary Approach to the Treatment of Co-occurring Opioid Use Disorder and Posttraumatic Stress Disorder in Pregnancy: A Case Report.

Goodman DJ, Milliken CU, Theiler RN, Nordstrom BR, Akerman SC.

J Dual Diagn. 2015;11(3-4):248-57. doi: 10.1080/15504263.2015.1104484.

15.

Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.

Gonzalez G, DiGirolamo G, Romero-Gonzalez M, Smelson D, Ziedonis D, Kolodziej M.

Drug Alcohol Depend. 2015 Nov 1;156:243-53. doi: 10.1016/j.drugalcdep.2015.09.020. Epub 2015 Sep 30.

16.

Buprenorphine dose induction in non-opioid-tolerant pre-release prisoners.

Vocci FJ, Schwartz RP, Wilson ME, Gordon MS, Kinlock TW, Fitzgerald TT, O'Grady KE, Jaffe JH.

Drug Alcohol Depend. 2015 Nov 1;156:133-8. doi: 10.1016/j.drugalcdep.2015.09.001. Epub 2015 Sep 7.

17.
18.

Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories.

Jacobs P, Ang A, Hillhouse MP, Saxon AJ, Nielsen S, Wakim PG, Mai BE, Mooney LJ, S Potter J, Blaine JD.

Am J Addict. 2015 Oct;24(7):667-75. doi: 10.1111/ajad.12288. Epub 2015 Sep 24.

19.

Sustained release oral morphine as an alternative to methadone for the treatment of opioid-use disorder post Torsades de Pointes cardiac arrest.

Walton G, Nolan S, Sutherland C, Ahamad K.

BMJ Case Rep. 2015 Sep 21;2015. pii: bcr2015210239. doi: 10.1136/bcr-2015-210239.

20.

Sleep-disordered breathing in patients with opioid use disorders in long-term maintenance on buprenorphine-naloxone: A case series.

DeVido J, Connery H, Hill KP.

J Opioid Manag. 2015 Jul-Aug;11(4):363-6. doi: 10.5055/jom.2015.0285.

Supplemental Content

Loading ...
Support Center